论文信息 - Thalidomide treatment of relapsed multiple myeloma patients and changes in circulating VEGF and bFGF - 字舞流文

Thalidomide treatment of relapsed multiple myeloma patients and changes in circulating VEGF and bFGF

G. Aloi | D. Teti | V. Pitini | C. Arrigo | M. Righi

[1] H. Goldschmidt,et al. Response to thalidomide in progressive multiple myeloma is not mediated by inhibition of angiogenic cytokine secretion , 2001, British journal of haematology.

[2] G. Martinelli,et al. Thalidomide in multiple myeloma, myelodysplastic syndromes and histiocytosis. Analysis of clinical results and of surrogate angiogenesis markers. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

[3] K. Wernecke,et al. Serum levels of the angiogenic cytokines basic fibroblast growth factor (bFGF), vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF) in multiple myeloma , 2001, European journal of haematology.

[4] H. Goldschmidt,et al. High plasma basic fibroblast growth factor concentration is associated with response to thalidomide in progressive multiple myeloma. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.